throbber
Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SLAYBACK PHARMA LLC
`
`Petitioner
`
`v.
`
`EYE THERAPIES LLC
`
`Patent Owner
`
`
`Case No. IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`PETITIONER’S OBJECTIONS TO
`PATENT OWNER’S EVIDENCE SUBMITTED WITH
`PATENT OWNER’S RESPONSE
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner Slayback Pharma LLC
`
`(“Petitioner”) objects to the admissibility of the following evidence filed by Patent
`
`Owner Eye Therapies LLC (“Patent Owner”) on August 29, 2022, with its Patent
`
`Owner’s Response.
`
`Petitioner’s objections are timely under 37 C.F.R. § 42.64(b)(1) because they
`
`are being filed and served within five business days of the filing of Patent Owner’s
`
`Response. Petitioner’s objections provide notice to Patent Owner that Petitioner
`
`may move to exclude these exhibits under 37 C.F.R. § 42.64(c).
`
`In this Paper, objection “R” is for lack of relevance or causing undue
`
`prejudice, pursuant to Federal Rules of Evidence (“FRE”) 401, 402, and/or 403.
`
`In this Paper, Petitioner’s objections to Patent Owner’s exhibits for hearsay
`
`(“H”), pursuant to FRE 802, apply to the extent Patent Owner seeks to rely on such
`
`exhibits for the truth of any matters stated in such exhibits and do not fall into any
`
`hearsay exception.
`
`In this Paper, objection “A” is for lack of authenticity, pursuant to FRE 901.
`
`In this Paper, objection “F” is for lack of foundation, pursuant to FRE 602.
`
`In this Paper, objection “I” is for improper expert testimony, pursuant to FRE
`
`701, 702, and/or 703.
`
`In this Paper, objection “L” is for calling for a legal conclusion.
`
`In this Paper, objection “NP” reflects that the exhibit was not published or
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`publicly available prior to the earliest filing date of the challenged patent, and
`
`therefore cannot be considered prior art. Petitioner objects to these exhibits to the
`
`extent Patent Owner relies on them for the knowledge of a POSA.
`
`Exhibit descriptions provided in the below table are taken from Patent
`
`Owner’s Updated Exhibit List and are used for identification purposes only.
`
`Petitioner’s use of Patent Owner’s exhibit descriptions does not indicate that
`
`Petitioner agrees with Patent Owner’s descriptions or any other characterizations of
`
`such exhibits.
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`OBJECTIONS
`
`Objections
`
`Description
`Bausch & Lomb, Inc., et al. v. Slayback
`Pharma LLC, et al. , C.A. 21-16766 (D.N.J.),
`Joint Discovery Plan submitted Feb. 3, 2022
`Bausch & Lomb, Inc., et al. v. Slayback
`Pharma LLC, et al. , C.A. 21-16766 (D.N.J.),
`Defendants’ First Set of Requests for
`Production to Plaintiffs Nos. 1-2 served on
`Dec. 29, 2021
`Bausch & Lomb, Inc., et al. v. Slayback
`Pharma LLC, et al. , C.A. 21-16766 (D.N.J.),
`ECF No. 15, Scheduling Order signed by the
`Honorable Douglas E. Arpert, U.S.M.J. on
`Feb. 15, 2022
`Bausch & Lomb, Inc., et al. v. Slayback
`Pharma LLC, et al. , C.A. 21-16766 (D.N.J.),
`ECF No. 11, Order Setting the Initial
`Scheduling Conference dated Dec. 15, 2021
`Notice of Paragraph IV Certification Re:
`Slayback Pharma LLC’s Brimondine Tartrate
`Ophthalmic Solution, 0.025%, U.S. Patent
`Nos. 8,293,742 and 9,259,425 dated Aug. 13,
`2021
`Bausch & Lomb, Inc., et al. v. Slayback
`Pharma LLC, et al. , C.A. 21-16766 (D.N.J.),
`ECF No. 1, Complaint for Patent
`Infringement filed Sept. 10, 2021
`Louis B. Cantor, “Brimondine in the
`treatment of glaucoma and ocular
`hypertension,” Therapeutics & Clinical Risk
`Mgmt., 2(4):337-346 (2006)
`U.S. Patent No. 6,982,079 B2, Compositions
`For Treating Hyperemia
`Ji Hoon Lee, et al., “Efficacy of brimonidine
`tartrate 0.2% ophthalmic solution in reducing
`halos after laser in situ keratomileusis,” J. of
`
`R
`
`R
`
`R
`
`R
`
`R
`
`R, H
`
`
`
`
`
`
`
`Exhibit
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`Cataract & Refractive Surgery, 34:963-967
`(2008)
`U.S. Patent No. 5,021,416, Method for Using
`(2-Imidazolin-2-Ylamino) Quinoxalines to
`Reduce or Maintain Intraocular Pressure
`Press Release, "New Survey From Bausch +
`Lomb and Glaucoma Research Foundation
`Reveals Emotional and Social Impact of
`Hyperemia on Glaucoma Patients" (Jan. 4,
`2022), https://www.bausch.com/our-
`company/recentnews/artmid/11336/articleid/6
`83
`Alphagan® (brimonidine tartrate ophthalmic
`solution) 0.5% and 0.2%, Alphagan® P
`(brimonidine tartrate ophthalmic solution)
`0.15%, Highlights of Prescribing Information
`(Dec. 20, 2001)
`Visine-A Label (June 14, 2002)
`Alphagan® P (brimonidine tartrate
`ophthalmic solution) 0.1 % and 0 .15%,
`Highlights of Prescribing Information (Aug.
`19, 2005)
`Alphagan™ (brimonidine tartrate ophthalmic
`solution) 0.2% Sterile, Approval Letter (Sept.
`6, 1996)
`Drugs@FDA Approved Drug Information,
`Alphagan 0.5%,
`https://www.accessdata.fda.gov/scripts/cder/d
`af/index.cfm?event=overview.process&App1
`No=020490
`Drugs@FDA Approved Drug Information,
`Alphagan 0.15%,
`https://www.accessdata.fda.gov/scripts/cder/d
`af/index.cfm?event=overview.process&Appl
`No=021262
`Press Release, “Allergan to focus on
`Alphagan-P, discontinue Alphagan (July 8,
`2002),
`
`
`
`R, H, A, NP
`
`
`
`H, A
`
`
`
`
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`
`
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`https://www.healio.com/news/ophthalmology/
`20120331/allergan-tofocus-on-alphagan-p-
`discontinue-alphagan
`Alphagan P (brimonidine tartrate ophthalmic
`solution) 0.1%, Approval Letter (Aug. 19,
`2005)
`
`2019
`
`2020
`
`CONFIDENTIAL Declaration of Robert J.
`Noecker, MD, MBA (Under Seal and Public
`versions)
`
`2021
`
`CONFIDENTIAL Declaration of Robert O.
`Williams, III, Ph.D. (Under Seal and Public
`versions)
`
`2022
`
`Declaration of Stephen G. Davies, D.Phil.
`
`2023
`
`CONFIDENTIAL Declaration of John Ferris
`(Under Seal and Public versions)
`
`R, H
`
`To the extent this
`declaration cites to an
`objected-to exhibit,
`Petitioner objects to the
`paragraph(s) in which
`said citation appears for
`the same reason that
`Petitioner objects to the
`cited exhibit.
`To the extent this
`declaration cites to an
`objected-to exhibit,
`Petitioner objects to the
`paragraph(s) in which
`said citation appears for
`the same reason that
`Petitioner objects to the
`cited exhibit.
`To the extent this
`declaration cites to an
`objected-to exhibit,
`Petitioner objects to the
`paragraph(s) in which
`said citation appears for
`the same reason that
`Petitioner objects to the
`cited exhibit.
`I (¶¶ 5, 7-8, 9, 14-18,
`20, 21-26)
`
`To the extent this
`declaration cites to an
`objected-to exhibit,
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`Petitioner objects to the
`paragraph(s) in which
`said citation appears for
`the same reason that
`Petitioner objects to the
`cited exhibit .
`
`I (¶¶ 107-112)
`
`To the extent this
`declaration cites to an
`objected-to exhibit,
`Petitioner objects to the
`paragraph(s) in which
`said citation appears for
`the same reason that
`Petitioner objects to the
`cited exhibit.
`
`2024
`
`CONFIDENTIAL Declaration of John C.
`Jarosz (Under Seal and Public versions)
`
`
`
`
`
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`USP 32, General Notices and Requirements,
`“Applying to Standards, Tests, Assays, and
`Other Specifications of the United States
`Pharmacopeia”, Pp. 1 - 12
`65 Fed. Reg. 83,041 (December 29, 2000)
`Skwietczynski, “Chapter 2 - Analysis of
`Medicinals”, Remington Essentials of
`Pharmaceuticals, edited by Linda Felton,
`(Pharmaceutical Press 2012), Pp. 9 - 28
`CONFIDENTIAL 3.2.P.5.6 Justification of
`Specifications (BAULUM00057392-
`57399) (Under Seal and Public versions)
`“Legal Recognition - Standards Categories”,
`The United States Pharmacopeia Convention,
`https://www.usp.org/about/legalrecognition/st
`andard-categories
`Agarwal, Priyanka, et al. "Review:
`Formulation Considerations for the
`Management of Dry Eye Disease."
`Pharmaceutics, vol. 13, no. 2, Feb. 2021 , pp.
`
`R
`
`
`
`R, NP
`
`R, H, A, NP
`
`R, H, A
`
`R, NP
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`1-19 (Agarwal 2021)
`21 CFR § 330.10 (2002) (21 CFR § 330.10) R, NP
`67 Fed. Reg. 3,060 (January 23, 2002)
`R
`Orange Approved Drug Products with
`Therapeutic Equivalence Evaluations, Patent
`and Exclusivity for N021770, (Brimonidine
`Tartrate (Alphagan P) Solution/Drops 0.1%),
`https://www.accessdata.fda.gov/scripts/cder/o
`b/patent_info.cfm?Product_No=00l&ApplNo
`=021770&Appl_type=N
`Orange Approved Drug Products with
`Therapeutic Equivalence Evaluations, Patent
`and Exclusivity for N021262, (Brimonidine
`Tartrate (Alphagan P) Solution/Drops 0.15%),
`https://www.accessdata.fda.gov/scripts/cder/o
`b/patent_info.cfm?Product_No=001&Appl_N
`o=021262&Appl_type=N
`“Drug Application Process for
`Nonprescription Drugs”,
`https://www.fda.gov/drugs/types-
`applications/drug-applicationprocess-
`nonprescription-drugs
`Zhu and Chauhan, “Effect of Viscosity on
`Tear Drainage and Ocular Residence Time”,
`Optometry and Vision Science, 85(8):E715-
`E725 (August 2008)
`Coffey et al., “Development of a non-settling
`gel formulation of 0.5% loteprednol etabonate
`for anti-inflammatory use as an ophthalmic
`drop”, Clinical Ophthalmology, 7:299-312
`(2013)
`Alphagan P (Brimonidine Tartrate)
`Ophthalmic Solution 0.15%, Center for Drug
`Evaluation and Research, Application No. 21-
`764, Chemistry Review(s),
`https://www.accessdata.fda.gov/drugsatfda_d
`ocs/nda/2001/21-
`262_Alphagan%20P%20Ophthalmic_chemr.p
`
`R
`
`R, NP
`
`
`
`2031
`2032
`
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`df
`Alphagan P (Brimonidine Tartrate)
`Ophthalmic Solution 0.1 %, Center for Drug
`Evaluation and Research, Application No. 21-
`770, Chemistry Review(s),
`https://www.accessdata.fda.gov/drugsatfda_d
`ocs/nda/2005/021770s000_ChemR.pdf
`de Mendoza et al., “Molecular recognition of
`oxoanions based on guanidinium receptors,”
`36 CHEM. Soc. REV. 198, 198 (2007) (de
`Mendoza 2007)
`Bagwell, Kyle, “The Economic Analysis of
`Advertising,” Columbia University
`Department of Economics Discussion Paper
`Series, Discussion Paper No.: 0506-01,
`August 2005.
`Congressional Budget Office, “Promotional
`Spending for Prescription Drugs,” December
`2, 2009.
`Ching, Andrew T. and Masakazu Ishihara,
`“Measuring the Information and Persuasive
`Roles of Detailing on Prescribing Decisions,”
`Management Science, July 2012, Vol. 58, No.
`7, 1374-1387
`Gonzalez, Agustin L., et al., “A survey of
`optometrists’ ophthalmic medication
`prescribing,” Clinical Optometry, March 5,
`2014, Vol. 6, 11-15.
`IRI, “New Product Pacesetters: Innovation
`Before the ‘New Normal,’” May 2020.
`Carlton, Dennis W. and Jeffery M. Perloff,
`Modern Industrial Organization, 4th Ed.,
`Pearson Education Limited 2015.
`Samuelson, Paul A. and William D.
`Nordhaus, Economics, 19th Ed., McGraw-
`Hill 2010.
`Spiegel, A.J. and C. F. Gerber, “The
`compatibility of tetrahydrozoline
`
`
`
`
`
`R
`
`R
`
`R, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, NP
`
`R, NP
`
`
`
`
`
`
`
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`2045
`
`2046
`
`2047
`
`2048
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A, L, NP
`
`hydrochloride solutions,” Journal of the
`American Pharmaceutical Association, July
`1959, Vol. 20, No. 7, 404-405.
`Thomas, Natalie A. "Secondary
`Considerations in Nonobviousness Analysis:
`The Use of Objective Indicia Following KSR
`v. Teleflex," New York University Law
`Review, December 2011, Vol. 86, No. 6,
`2070-2112.
`Thomas, Randall and Ron Melton, “2016
`Clinical Guide to Ophthalmic Drugs,” Review
`of Optometry, May 15, 2016, 1-51.
`BAU-LUM00063901 (Bausch & Lomb Press
`Release, “Nielsen’s BASES Names Lumify
`Eye Drops to 2020 U.S. BASES Top 25
`Breakthrough Innovations List”)
`CONFIDENTIAL LUM.0205.USA.21
`(Under Seal and Public versions)
`Reserved
`Reserved
`LUM.1827.USA.21 (Lumify Brochure)
`Lumify_v9 - PRC APRVD
`CONFIDENTIAL IRI Panel Data (Under
`Seal and Public versions)
`CONFIDENTIAL IRI Point-of-Sale Data
`(Under Seal and Public versions)
`Visine Supplemental Approval, October 17,
`2018
`Lumify Supplemental Approval, April 30,
`2019
`Lumify Supplemental Approval, February 21,
`2019
`Lumify Supplemental Approval, March 5,
`2020
`Lumify Supplemental Approval, November
`R, H, NP
`29, 2021
`Lumify Supplemental Approval, September R, H, NP
`
`NP
`
`R, H, A, NP
`
`R, H, A, F, NP
`
`
`H, A, NP
`H, A, NP
`H, A, NP
`
`H, A, NP
`
`R, H, NP
`
`R, H, NP
`
`R, H, NP
`
`R, H, NP
`
`
`
`
`
`
`2049
`
`2050
`
`2051
`
`2052
`2053
`2054
`2055
`2056
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`2064
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H
`
`R, H
`
`R, H
`
`R, H
`
`R, H
`
`R, H
`
`R, H
`
`R, H
`
`23, 2020
`Lumify NDA Approval, December 22, 2017 R, H, NP
`Lumify NDA Summary Overview, November
`R, H, NP
`29, 2017
`Bausch+ Lomb Corporation SEC Form 10-Q
`for the quarterly period ended March 31, 2022 R, H
`Bausch+ Lomb Corporation QI 2022
`R, H
`Financial Results
`Bausch+ Lomb Corporation SEC Form S-1,
`January 13, 2022
`Bausch+ Lomb Corporation SEC Form S-IA,
`April 28, 2022
`Valeant Phannaceuticals International, Inc.
`2017 Annual Report
`Bausch Health Companies Inc. 2018 Annual
`Report
`Bausch Health Companies Inc. QI 2019
`Financial Results
`Bausch Health Companies Inc. SEC Form 10-
`K for the fiscal year ended December 31,
`2021
`Bausch Health Companies Inc. Q4 and FY
`2021 Financial Results
`Johnson & Johnson SEC Form 10-K for the
`fiscal year ended December 31, 2006
`https://www.accessdata.fda.gov/scripts/cder/d
`af/index.cfm?event=overview.process&App1
`No=020065 (viewed August 16, 2022)
`https://www.accessdata.fda.gov/scripts/cder/o
`b/results_product.cfm?Appl_Type-
`N&Appl_No=020226#4 l 039 (viewed
`August 16, 2022)
`https://www.accessdata.fda.gov/scripts/cder/o
`b/patent_info.cfm?Product_No=00l&Appl_N
`o=208144&Appl_type=N (viewed August 22,
`2022)
`https://www.accessdata.fda.gov/scripts/cder/d
`af/index.cfm?event=o
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`2065
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2072
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A, NP
`
`R, H, A
`
`R, H, A
`
`R, H, A, NP
`
`verview.process&App1No=020485 (viewed
`July 11, 2022)
`https://www.amazon.com/Lumify-Redness-
`Reliever-Drops-7-
`5mL/dp/B07BVYZL88/ref=sr_1_4?keywords
`=lumify+drops&qid=1656719062&sr=8-4
`(viewed July 1, 2022)
`https://www.bausch.com/about-bausch-
`lomb/locations/ (viewed July 8, 2022)
`https://www.bausch.com/news/messages-
`from-ceo/article/I/ (viewed July 8, 2022)
`https://www.bausch.com/products/otc-eye-
`care- supplements/redness-relief/ (viewed
`August 15, 2022)
`https://www.businesswire.com/news/home/20
`220729005454/en/Dr.-Reddys-Laboratories-
`enters-into-a-licensing-agreement-with-
`Slayback-Pharma-to-%E2%80%A61/3
`(viewed August 22, 2022)
`https://www.cleareyes.com/eye-
`drops/redness-relief (viewed July 11, 2022)
`https://www.cleareyes.com/eye-
`drops/sensitive-eyes-relief/clear-eyes-
`complete-sensitive-eyes#ingredients
`(viewed August 15, 2022)
`https://www.cleareyes.com/eye-
`drops/redness-relief/clear-eyes- cooling-
`comfort-itchy-eye-relief#ingredients (viewed
`August 15, 2022)
`https://www.cleareyes.com/eye-
`drops/redness-relief/clear-eyes- maximum-
`redness-relief-eye-drops#ingredients (viewed
`August 15, 2022)
`https://www.cleareyes.com/eye-
`drops/redness-relief/clear-eyes-redness-relief-
`eye-drops#directions (viewed August 16,
`2022)
`https://www.cleareyes.com/eye-
`drops/redness-relief/clear-eyes-redness-relief- R, H, A, NP
`
`R, H, A
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`
`
`
`
`
`2081
`
`2082
`
`2083
`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A, NP
`
`eye-drops#ingredients (viewed August 15,
`2022)
`https://www.cleareyes.com/eye-drops/for-
`travelers/travelers-eye-relief#ingredients
`(viewed August 15, 2022)
`https://www.cvs.com/shop/personal-care/eye-
`care/drops-
`lubricants/qiCVS_Health/Eye_Drops/brpt
`(viewed August 8, 2022)
`https://www.cvs.com/shop/lumify-redness-
`reliever-eye-drops-prodid-1910106 (viewed
`July 1, 2022)
`https://dailymed.nlm.nih.gov/dailymed/drugln
`fo.cfm?setid=69166dec-fb86-4c76-9efe-
`88c3bb12a8f0 (viewed August 15, 2022)
`https://dailymed.nlm.nih.gov/dailymed/drugln
`fo.cfm?setid=e3c41a58-fc93-4e6c-99be-
`0529edfb54a4 (viewed August 16, 2022)
`https://eyewire.news/news/dr-reddys-
`laboratories-enters-into-a-licensing-
`agreement-to-obtain-rights-for-the-private-
`label-version-of-lumify-in-the-
`us?c4src=article:infinite-scroll (viewed
`August 16, 2022)
`https://fda.report/Company/Bausch-Lomb-Inc
`(viewed August 15, 2022)
`https://fda.report/Company/Prestige-Brands-
`Holdings-Inc (viewed August 15, 2022)
`https://www.glamour.com/gallery/best-
`beauty-innovators-of-2022 (viewed July 23,
`2022)
`https://intothegloss.com/2021/12/top-25-
`2021-cheap-thrills-beauty- under-35-dollars/
`(viewed August 22, 2022)
`https://introwellness.com/eyes/drops/lumify-
`eye-drops-review/ (viewed August 16, 2022) R, H, A
`https://ir.bauschhealth.com/news-
`R, H, A
`releases/2018/05-07-2018- 130249958
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`
`
`
`2092
`
`2093
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`2102
`
`2103
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`(viewed July 1, 2022)
`https://ir.bauschhealth.com/news-
`releases/2017/12-22-2017- 200318686
`(viewed August 16, 2022)
`https://ir.bauschhealth.com/news-
`releases/2018/07-13-2018 (viewed August 15,
`2022)
`https://ir.bauschhealth.com/news-
`releases/2013/27-05-2013 (viewed August 16,
`2022)
`https:/fir.nielsen.com/news-events/press-
`releases/news- details/2020/Capitalizing-on-
`Innovation-Trends-Today-Will-Drive-
`Business-Growth-in-the-New-
`Normal/default.aspx (viewed August 16,
`2022)
`https://www.lumifydrops.com/faqs (viewed
`July 22, 2022)
`https://www.lumifydrops.com (viewed
`August 23, 2022)
`https://www.lumifydrops.com/professional/cli
`nical-information (viewed July 12, 2022)
`https://www.lumifydrops.com/professional
`(viewed August 15, 2022)
`https://www.lumifydrops.com/lumify-science
`(viewed July 12, 2022)
`https://www.mckinsey.com/industries/life-
`sciences/our-insights/the- secret-of-
`successful-drug-launches (viewed August 16,
`2022)
`https://www.newyou.com/beauty-
`awards/new-beauty-awards-2018/ (viewed
`July 23, 2022)
`https://www.ophthalmologyweb.com/1315-
`News/346489-FDA-Approves-LUMIFY-a-
`Brimonidine-OTC-for-Ocular-Redness/
`(viewed August 16, 2022)
`https://www.optometricmanagement.com/issu R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`
`
`
`2104
`
`2105
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`
`2111
`
`2112
`
`2113
`
`2114
`
`2115
`
`2116
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`es/2006/november-2006/how-to-maximize-
`prescription-authority (viewed August 22,
`2022)
`https://www.optometrytimes.com/view/b-l-
`licenses-new-technology-treating-ocular-
`redness?qt-resource_topics_rightrail=l
`(viewed August 16, 2022)
`https://patents.bausch.com (viewed August
`17, 2022)
`Advanced Eye Relief Drug Facts, available at
`https://pi.bausch.com/globalassets/pdf/downlo
`ads/consumer/vision-care/safety/advanced-
`eye-relief-redness-drug-facts.pdf
`Advanced Eye Relief Max Drug Facts,
`available at
`https://pi.bausch.com/globalassets/pdf/downlo
`ads/consumer/vision-care/safety/advanced-
`eye-relief-maximum-redness-drug-facts.pdf
`https://pink.pharmaintelligence.informa.com/
`RS148905/Lumify-Ad-Launches-As-Bausch-
`Spends-More-Behind-OTC-Eye-Care-Brands
`(viewed August 16, 2022)
`https://pitchbook.com/profiles/company/4926
`64-60#overview (viewed August 18, 2022)
`https://www.prestigebrands.com/products/eye
`-ear-nose-throat/clear-eyes (viewed July 11,
`2022)
`https://www.prnewswire.com/news-
`releases/bausch--lomb-licenses-new-
`technology-with-potential-to-treat-millions-
`affected-by-ocular-redness-185856742.html
`(viewed August 16, 2022)
`https://www.pmewswire.com/news-
`releases/nielsens-bases-names-lumify-eye-
`drops-to-2020-us-bases-top-25-breakthrough-
`innovations-list-301143761.html (viewed July
`17, 2022)
`https://www.prnewswire.com/news-
`releases/slayback-pharma-announces-fda-
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`
`
`
`2117
`
`2118
`
`2119
`
`2120
`
`2121
`
`2122
`
`2123
`
`2124
`
`2125
`
`2126
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A
`
`R, H, A
`
`approval-of-hydroxyprogesterone-caproate-
`injection-usp-1-250-mg-5-ml-in-a-multi-dose-
`vial-the-first-generic- equivalent-of-makena-
`injection-1-250-mg-5-ml-multi-dose-vial-
`300771547.html (viewed August 19, 2022)
`https://www.prnewswire.com/news-
`releases/slayback-pharma-announces-the-
`final-approval-and-launch-of-generic-zovirax-
`acyclovir-ointment-5-300383519.html
`(viewed August 16, 2022)
`https://www.prnewswire.com/news-
`releases/slayback-pharma-announces-
`approval-of-icatibant-injection-30-mg3-ml-l0-
`mg-ml- generic-equivalent-of-firazyr-
`301123357.html (viewed July 8, 2022)
`https://www.prnewswire.com/news-
`releases/slayback-pharma-announces-launch-
`of-merzee-norethindrone-acetate-and-ethinyl-
`estradiol-capsules-and-ferrous-fumarate-
`capsules-1-mg20-mcg- generic-equivalent-of-
`taytulla-301222104.html (viewed July 8,
`2022)
`https://www.reviewofoptometry.com/article/w
`hen-to-prescribe-an-otc-allergy-drop (viewed
`August 22, 2022)
`https://www.riteaid.com/shop/ra-rednss-relf-
`eye-drp-5z-0354534 (viewed August 8, 2022) R, H, A
`https://www.riteaid.com/shop/rite-aid-eye-
`care-sterile-eye-drops-0-5-fl-oz (viewed
`August 8, 2022)
`https://rohtoeyedrops.com/collections/redness
`-reliever/products/rohto_all_in_one_multi-
`symptom_eye_drops (viewed August 18,
`2022)
`https://rohtoeyedrops.com/collections/redness
`-reliever/products/cool_relief_eye_drops
`(viewed August 18, 2022)
`https://rohtoeyedrops.com/collections/redness
`-
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`
`
`
`2127
`
`2128
`
`2129
`
`2130
`
`2131
`
`2132
`
`2133
`
`2134
`
`2135
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`reliever/products/rohto_max_strength_redness
`_relief_cooling_eye_drops (viewed August
`18, 2022)
`https://rohtoeyedrops.com/collections/redness
`-reliever/products/rohto-eye-drops-optic-glow
`(viewed August 18, 2022)
`https://rohtoeyedrops.com/collections/redness
`-reliever/products/rohto-digi-eye-digital-eye-
`strain-eye-drops (viewed August 18, 2022)
`https://rohtoeyedrops.com/collections/redness
`-reliever (viewed July 11, 2022)
`https://www.similasanusa.com/redness-itchy-
`eye-reliefl'M(viewed August 8, 2022)
`https://slayback-pharma.com/about-us/
`(viewed August 15, 2022)
`https://slayback-pharma.com/products/
`(viewed August 16, 2022)
`https://slayback-pharma.com (viewed August
`22, 2022)
`https://www.target.com/p/lumify-eye-drops/-
`/A-54293362 (viewed July 1, 2022)
`https://www.thezoereport.com/beauty-awards
`(viewed July 23, 2022)
`https://us.mentholatum.com/about-us/
`(viewed July 11, 2022)
`https://www.verywellhealth.com/best-eye-
`drops-for-red-eyes- 5184209 (viewed July
`12, 2022)
`Reserved
`https://www.walgreens.com/store/c/productlis
`t/walgreens-redness-relief/N=361377-l18
`(viewed August 8, 2022)
`https://www.walmart.com/ip/LUMIFY-
`Redness-Reliever-Eye-Drops-Brimonidine-
`Tartrate-Ophthalmic-Solution-0-025-from-
`Bausch-Lomb-0-08-Fl-Oz-2-5-
`mL/193381081?athbdg=L1600 (viewed July
`1, 2022)
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`R, H, A
`
`
`
`R, H, A
`
`R, H, A
`
`2136
`
`2137
`
`2138
`
`2139
`
`2140
`
`2141
`
`2142
`
`2143
`
`2144
`
`2145
`
`2146
`
`2147
`
`2148
`
`2149
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`R, H, A
`
`R, H, A
`
`https://walrus.com/questions/lumify-vs-
`visine-what-is-the-difference (viewed August
`16, 2022)
`https://www.accessdata.fda.gov/drugsatfda_d
`ocs/label/2020/208144Origls006lbl.pdf
`(viewed August 18, 2022)
`"LUMIFY™ Redness Reliever Eye Drops
`Honored By The National Association of
`Chain Drug Stores As Product Showcase
`Winner", PRNewswire (September 10, 2018)
`Rory Evans and Maureen Choi, "The Best of
`beauty 2019", Brides (April/May 2019)
`"NewBeauty 2019 Award Winners: Best
`Innovations", NewBeauty (March 8, 2019)
`"Beauty Awards, The Best Even More, Never
`Knew We Needed", New Beauty (2022)
`CONFIDENTIAL "Lumify ECP A&U
`Report", 27 March 2020
`(Under Seal and Public versions)
`"Healthcare", Ispos,
`https://www.ipsos.com/en-hk/healthcare
`"LUMIFY™ Redness Reliever Eye Drops
`Honored By The National Association of
`Chain Drug Stores As Product Showcase
`Winner", PRNewswire (September 10, 2018)
`Bausch Health Q2 2022 Earning Presentation H, A
`"About Us", IRI available at
`https://www.iriworldwide.com/en-
`us/company/about-us (last visited July 25,
`2022)
`U.S. Patent No. 8,293,742 (filed July 27,
`2009) (issued Oct. 23, 2012) (’742 Patent)
`(Color)
`Petitioner reserves all
`Deposition Transcript of Dr. Neal A. Sher,
`objections made at the
`M.D.
`time of the deposition.
`"The Science of Lumify",
`https://www.lumifydrops.com/lumify- science H, A, NP
`
`H, A
`
`H, A
`
`H, A
`
`H, A
`
`R, H, A
`
`R, H, A
`
`H, A
`
`R, H, A
`
`
`
`2150
`
`2151
`
`2152
`
`2153
`
`2154
`
`2155
`
`2156
`
`2157
`
`2158
`
`2159
`
`2160
`
`2161
`
`2162
`
`2163
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`(The Science of Lumify)
`"Lumify Lovers of the Month - Meet Dillon
`Pena",
`https://www.lumifydrops.com/lovers/march-
`202 l-dillon-pena (Lumify Lovers)
`"Bausch+ Lomb Receives FDA Approval of
`Lumify™ - The only Over-the-Counter Eye
`Drop with Low-Dose Brimonidine for the
`Treatment of Eye Redness", (December 22,
`2017),
`https://ir.bauschhealth.com/news-
`releases/2017/12-22-2017- 200318686
`CONFIDENTIAL 10-100-0008 Clinical
`Study Report (Excerpted)
`(Under Seal and Public versions)
`CONFIDENTIAL 11-100-0015 Clinical
`Study Report (Excerpted)
`(Under Seal and Public versions)
`CONFIDENTIAL 13-100-0005 Clinical
`Study Report (Excerpted)
`(Under Seal and Public versions)
`Robert J. Derick, "Adrenergic Agonist
`Medications: Basic Mechanisms." Journal of
`Glaucoma, 4(Supp. 1):Sl-S7 (1995) (Derick
`1995)
`Drug Application Process for Nonprescription
`Drugs, FDA,
`https://www.fda.gov/drugs/types-
`applications/drug-application- process-
`nonprescription-drugs (FDA Website)
`Definition of Ciliary Body - NCI Dictionary
`Cancer Terms,
`https://www.cancer.gov/publications/dictionar
`ies/cancer-terms/def/ciliary-body
`Eyes: How They Work, Anatomy & Common
`Conditions, Cleveland Clinic,
`https://my.clevelandclinic.org/health/body/21
`823- eyes
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`
`
`R, H, A, NP
`
`R, H, A, NP
`
`R, H, A, NP
`
`2164
`
`2165
`
`2166
`
`2167
`
`2168
`
`2169
`
`2170
`
`2171
`
`2172
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`Glaucoma: Symptoms and causes, Mayo
`Clinic, https://www.mayoclinic.org/diseases-
`conditions/glaucoma/symptoms-causes/syc-
`20372839?p=l
`S. J. Morgan, "Chemical Bums of the Eye:
`Causes and Management," British Journal of
`Ophthalmology, 71:854-857 (1987) (Morgan
`1987)
`G. Munoz et al., "Increased risk for flap
`dislocation with perioperative brimonidine
`use in femtosecond laser in situ
`keratomileusis," J. Cataract Refract. Surg.,
`35:1338-1342 (2009)
`G. Raviola, "Conjunctiva! and Episcleral
`Blood Vessels are Permeable to Blood-borne
`Horseradish Peroxidase", Invest. Ophthalmol.
`Vis. Sci., 24:725-736, (June 1983) (Raviola)
`"Scientists discover why cornea is transparent
`and free of blood vessels, allowing vision",
`Schepens Eye Research Institute (July 17,
`2006), https://www.eurekalert.org/news-
`releases/652982
`Sclera: Definition, Anatomy & Function,
`Cleveland Clinic,
`https://my.clevelandclinic.org/health/body/22
`088-sclera
`"Is the sclera avascular (without blood
`vessels)?", American Academy of
`Ophthalmology (January 31, 2019),
`https://www.aao.org/eye-health/ask-
`ophthalmologist-q/is-sclera- avascular-
`without-blood-vessels
`N. Sher, "Red eye: What's dangerous? What's
`not?", Patient Care, 18(19):87-114,
`(November 15, 1984)
`Highlights of Prescribing Information for
`SIMBRINZATM (brinzolamide/brimonidine
`tartrate ophthalmic suspension) 1%/0.2%
`
`R, H, A, NP
`
`R
`
`R
`
`
`
`R, H, A
`
`R, H, A, NP
`
`R, H, A, NP
`
`R
`
`R, H, A
`
`2173
`
`2174
`
`2175
`
`2176
`
`2177
`
`2178
`
`2179
`
`2180
`
`2181
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`C. N. Soparkar et al., "Acute and Chronic
`Conjunctivitis Due to Over-the-counter
`Ophthalmic Decongestants," Arch.
`Ophthalmol., 115:34-38 (1997) (Soparkar)
`S. L. Spector, et al., "Conjunctivitis
`medicamentosa," J. Allergy Clin. Immunol.,
`94:134-136 (1994) (Spector)
`M. Stafford-Smith, MD. et al., "Alpha-
`adrenergic mRNA subtype expression in the
`human nasal turbinate," Can. J. Anesth.,
`54(7):549-555 (2007) (Stafford-Smith)
`M. Abelson, et al., "The Truth about
`Tachyphylaxis," Review of Ophthalmology
`(March 16, 2006),
`https://www.reviewofophthalmology.com/arti
`cle/the-truth-about- tachyphylaxis (Abelson
`2006)
`0. Uretmen, et al., Letters to the Editor:
`Prophylactic Brimonidine Before LASIK
`(2003) (Uretmen)
`R.R. Ruffolo, Jr., "a-Adrenoceptors", Monogr.
`Neural. Sci.,10:224- 253 (Karger, Basel
`1984).
`Reserved
`Reserved
`U.S. Patent 3,890,319 (filed Feb. 14, 1973)
`(issued June 17, 1975)
`('319 patent)
`Prescribing Information Label for Lumify®
`(Lumify®label)
`Prescribing Information Label for Naphcon-
`A® (Naphcon-A® label)
`Prescribing Information for Visine®L.R.
`(Visine®L.R. label)
`Prescribing Information for Visine®Original
`(Visine®Original label)
`CONFIDENTIAL NDA 208144, Section 2.2
`Introduction (Excerpted) (Under Seal and
`
`
`
`
`
`R
`
`
`
`
`
`R
`
`
`
`
`R
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`H, A, NP
`
`2182
`
`2183
`
`2184
`
`2185
`
`2186
`
`2187
`
`2188
`2189
`
`2190
`
`2191
`
`2192
`
`2193
`
`2194
`
`2195
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`Public versions)
`CONFIDENTIAL NDA 208144, Section
`2.3.P.1.1 Finished Product Composition
`(Excerpted) (Under Seal and Public versions)
`K. S. Bower, Overview of Refractive Surgery,
`Am. Fm. Physician. 2001;64(7):1183-1191.
`Deposition Transcript of Paul A. Laskar,
`Ph.D., dated August 4, 2022
`Enhancing the Management of Red Eye,
`https://www.lumifydrops.com/siteassets/ecp/p
`dfs/Lumify-news.pdf
`P. Watts & N. Hawksworth, Delayed
`hypersensitivity to brimonidine tartrate 0.2%
`associated with high intraocular pressure, Eye
`(2002) 16, 132-135
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Declaration of David Fisher in Response to
`Slayback’s Objections to Patent Owner's
`Exhibit No. 2011 (served but not filed on June
`16, 2022)
`
`H, A, NP
`
`
`Petitioner reserves all
`objections made at the
`time of the deposition
`
`H, A, NP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I (¶¶ 7-8)
`
`2196
`
`2197
`
`2198
`
`2199
`
`2200
`
`2201
`2202
`2203
`2204
`2205
`2206
`2207
`2208
`2209
`2210
`
`2211
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`Respectfully submitted,
`
`/Linnea P. Cipriano/
`Linnea P. Cipriano
`(Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 937-2204
`lcipriano@goodwinlaw.com
`
`Counsel for Petitioner
`Slayback Pharma LLC
`
`September 6, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case IPR2022-00142
`U.S. Patent No. 8,293,742
`
`
`CERTIFICATE OF SERVICE
`
`I, Linnea P. Cipriano, certify that I caused to be served a true and correct
`
`copy of
`
`the foregoing PETITIONER’S OBJECTIONS TO PATENT
`
`OWNER’S EVIDENCE SUBMITTED WITH PATENT OWNER’S
`
`RESPONSE by email, as follows:
`
`Bryan Diner
`
`bryan.diner@finnegan.com
`
`Justin Hasford
`
`Justin.hasford@finnegan.com
`
`Caitlin O’Connell caitlin.oconnell@finnegan.com
`
`Christina Yang
`
`christina.yang@finnegan.com
`
`September 6, 2022
`
`
`
`
`
`
`
`
`
`
`/Linnea P. Cipriano/
`Linnea P. Cipriano
`(Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8000
`Fax: (212) 937-2204
`lcipriano@goodwinlaw.com
`
`Counsel for Petitioner
`Slayback Pharma LLC
`
`
`
`
`
`
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket